Aktuellt
SENASTE
Earlier today, Alzecure announced that it had received indicative data on blood-brain-barrier penetration – that a high enough concentration reaches the brain - from its ongoing phase I MAD study with small molecule candidate ACD856 (symptomatic alzheimer’s/cognitive decline). While it was expected from us, we are pleased to learn that this important step is under control. We will give a more extensive take once the full data is released.
LÄS MER
